why choose us

First received: October 15, 2022

Clinical Trial: Study of Zotiraciclib for Recurrent High-Grade Gliomas With Isocitrate Dehydrogenase 1 or 2 (IDH1 or IDH2) Mutations

Study Status: Completed

Recruit Status: RECRUITING

Condition: Brain Tumor

Study Type: INTERVENTIONAL


Official Title: A Phase I/II Study of Zotiraciclib for Recurrent High-Grade Gliomas With Isocitrate Dehydrogenase 1 or 2 (IDH1 or IDH2) Mutations

Brief Summary: Background:Diffuse gliomas are tumors that affect the brain and spinal cord.Gliomas that develop in people with certain gene mutations (IDH1 or IDH2) are especially aggressive.Better treatments are needed.Objective:To see if a study drug (zotiraciclib) is effective in people with recurrent diffuse gliomas who have IDH1 or IDH2 mutations.Eligibility:People aged 18 years and older with diffuse gliomas that returned after treatment.They must also have mutations in the IDH1 or IDH2 genes.Design:Participants will be…

Read more